Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026
Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026
Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026
Company Medical Device

Sino Medical Sciences Technology Secures TFDA Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Nov 3, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection

Fineline Cube Nov 3, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...

Company Drug

I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA

Fineline Cube Nov 3, 2023

China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...

Company

Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances

Fineline Cube Nov 3, 2023

Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...

Company

Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales

Fineline Cube Nov 3, 2023

US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023,...

Company Drug

Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program

Fineline Cube Nov 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...

Company Deals

AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies

Fineline Cube Nov 2, 2023

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...

Company

Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023

Fineline Cube Nov 2, 2023

Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for...

Company Drug

EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting

Fineline Cube Nov 2, 2023

Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...

Company

GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%

Fineline Cube Nov 2, 2023

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...

Company Deals

We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development

Fineline Cube Nov 2, 2023

Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...

Company Drug

Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...

Company

Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials

Fineline Cube Nov 2, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...

Company Drug

Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial

Fineline Cube Nov 2, 2023

China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...

Company Drug

Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial

Fineline Cube Nov 2, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...

Company Drug

Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study

Fineline Cube Nov 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...

Company Deals

3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab

Fineline Cube Nov 2, 2023

China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...

Company Deals

Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma

Fineline Cube Nov 2, 2023

US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...

Company Drug

Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery

Fineline Cube Nov 1, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...

Posts pagination

1 … 497 498 499 … 713

Recent updates

  • Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
  • Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
  • HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
  • AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
  • Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.